TY  - JOUR
AU  - Wolin, Edward
AU  - Mita, Alain
AU  - Mahipal, Amit
AU  - Meyer, Tim
AU  - Bendell, Johanna
AU  - Nemunaitis, John
AU  - Munster, Pam N
AU  - Paz Ares, Luis Gonzaga
AU  - Filvaroff, Ellen H
AU  - Li, Shaoyi
AU  - Hege, Kristen
AU  - de Haan, Hans
AU  - Mita, Monica
PY  - 2019
DO  - 10.1371/journal.pone.0221994
SN  - 1932-6203
UR  - http://hdl.handle.net/20.500.12105/9369
AB  - Second-generation mammalian target of rapamycin (mTOR) inhibitors such as CC-223 may have theoretical advantages over first-generation drugs by inhibiting TOR kinase in mTOR complex 1 (mTORC1) and 2 (mTORC2), potentially improving clinical efficacy...
LA  - eng
PB  - Public Library of Science (PLOS)
KW  - Administration, Oral
KW  - Adult
KW  - Aged
KW  - Carcinoid Tumor
KW  - Cohort Studies
KW  - Female
KW  - Gastrointestinal Neoplasms
KW  - Humans
KW  - Male
KW  - Maximum Tolerated Dose
KW  - Mechanistic Target of Rapamycin Complex 1
KW  - Mechanistic Target of Rapamycin Complex 2
KW  - Middle Aged
KW  - Neuroendocrine Tumors
KW  - Pyrazines
TI  - A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms
TY  - journal article
ER  -